[go: up one dir, main page]

CY1114140T1 - Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο - Google Patents

Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο

Info

Publication number
CY1114140T1
CY1114140T1 CY20131100116T CY131100116T CY1114140T1 CY 1114140 T1 CY1114140 T1 CY 1114140T1 CY 20131100116 T CY20131100116 T CY 20131100116T CY 131100116 T CY131100116 T CY 131100116T CY 1114140 T1 CY1114140 T1 CY 1114140T1
Authority
CY
Cyprus
Prior art keywords
cancer
pyridinone
components
compounds
formula
Prior art date
Application number
CY20131100116T
Other languages
English (en)
Inventor
Robert M Borzilleri
Zhen-Wei Cai
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1114140T1 publication Critical patent/CY1114140T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Αποκαλύπτονται ενώσεις του Χημικού Τύπου (I) και άλατα εξ' αυτών. Επίσης, αποκαλύπτονται μέθοδοι χρήσης των ενώσεων στην αγωγή των υπερπλαστικών παθήσεων, όπως είναι ο καρκίνος, και των φαρμακευτικών συνθέσεων περιλαμβάνοντας μια τουλάχιστον ένωση του Χημικού Τύπου (I) ή ένα φαρμακευτικώς αποδεκτό άλας.
CY20131100116T 2008-01-23 2013-02-08 Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο CY1114140T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2284808P 2008-01-23 2008-01-23
EP09704457A EP2235002B1 (en) 2008-01-23 2009-01-22 4-pyridinone compounds and their use for cancer

Publications (1)

Publication Number Publication Date
CY1114140T1 true CY1114140T1 (el) 2016-07-27

Family

ID=40637826

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100116T CY1114140T1 (el) 2008-01-23 2013-02-08 Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο

Country Status (22)

Country Link
US (2) US8124768B2 (el)
EP (1) EP2235002B1 (el)
JP (1) JP5314050B2 (el)
KR (1) KR101596527B1 (el)
CN (1) CN101977906B (el)
AU (1) AU2009206440B2 (el)
BR (1) BRPI0906444B8 (el)
CA (1) CA2713111C (el)
CO (1) CO6230986A2 (el)
CY (1) CY1114140T1 (el)
DK (1) DK2235002T3 (el)
EA (1) EA017736B1 (el)
ES (1) ES2398335T3 (el)
HK (1) HK1143157A1 (el)
HR (1) HRP20130040T1 (el)
IL (1) IL207212A (el)
NZ (1) NZ586630A (el)
PL (1) PL2235002T3 (el)
PT (1) PT2235002E (el)
SI (1) SI2235002T1 (el)
WO (1) WO2009094417A1 (el)
ZA (1) ZA201005248B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004018A (es) 2008-10-14 2011-06-24 Ning Xi Compuestos y metodos de uso.
JP5583751B2 (ja) 2009-03-21 2014-09-03 クイ ニング アミノエステル誘導体、その塩、及び使用方法
EP2563773A1 (en) 2010-04-29 2013-03-06 Deciphera Pharmaceuticals, LLC Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
MY165215A (en) 2012-01-31 2018-03-09 Daiichi Sankyo Co Ltd Pyridone derivatives
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
JP6342393B2 (ja) 2012-07-28 2018-06-13 カリター・サイエンシーズ・エルエルシー 置換型ピラゾロン化合物及び使用方法
US9102624B2 (en) * 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) * 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
TWI690525B (zh) 2014-07-07 2020-04-11 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
CN105153026B (zh) * 2015-08-21 2018-02-02 江西科技师范大学 含联芳基酰胺结构的索拉非尼衍生物及其制备方法和应用
TWI745824B (zh) * 2019-01-03 2021-11-11 美商亞雷生物製藥股份有限公司 作為tam及met激酶抑制劑之喹啉化合物
EP4332106A4 (en) * 2021-06-22 2024-10-30 LG Chem, Ltd. NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR
TW202428285A (zh) * 2022-09-28 2024-07-16 大陸商上海濟煜醫藥科技有限公司 含磷類化合物及其製備方法和醫藥應用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430885A3 (en) 1989-12-01 1991-11-06 Ciba-Geigy Ag Anthelmintical compounds
WO1997017329A1 (fr) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant
WO1999065867A1 (en) * 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6355660B1 (en) * 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
JP2003528806A (ja) * 1999-07-20 2003-09-30 ダウ・アグロサイエンス・エル・エル・シー 殺菌・殺カビ性複素環式芳香族アミドおよびそれらの組成物、使用および製造方法
HUP0300059A3 (en) 1999-09-21 2003-08-28 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical compositions containing the compounds and use of the new and known quinazoline derivatives against proliferative disease
CA2401984A1 (en) * 2000-03-22 2001-09-27 Merck Frosst Canada Inc. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
FR2812633A1 (fr) * 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
SE0102384D0 (sv) * 2001-07-03 2001-07-03 Pharmacia Ab New compounds
AU2002344567A1 (en) * 2001-11-28 2003-06-10 Daiso Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
JP4829506B2 (ja) * 2004-02-17 2011-12-07 石原産業株式会社 チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
AU2005245386B2 (en) * 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7732613B2 (en) * 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007035428A1 (en) * 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7348325B2 (en) * 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2531396T3 (es) 2008-01-23 2015-03-13 Bristol Myers Squibb Co Proceso para preparar compuestos de piridinona

Also Published As

Publication number Publication date
HRP20130040T1 (hr) 2013-02-28
AU2009206440A1 (en) 2009-07-30
CN101977906A (zh) 2011-02-16
CA2713111A1 (en) 2009-07-30
CO6230986A2 (es) 2010-12-20
US20120114643A1 (en) 2012-05-10
ES2398335T3 (es) 2013-03-15
DK2235002T3 (da) 2013-03-11
US8124768B2 (en) 2012-02-28
CA2713111C (en) 2015-06-30
JP5314050B2 (ja) 2013-10-16
SI2235002T1 (sl) 2013-06-28
NZ586630A (en) 2011-12-22
EA017736B1 (ru) 2013-02-28
EA201001196A1 (ru) 2011-02-28
BRPI0906444B1 (pt) 2021-03-16
CN101977906B (zh) 2014-11-05
BRPI0906444B8 (pt) 2021-05-25
ZA201005248B (en) 2011-09-28
AU2009206440B2 (en) 2013-08-15
US20110034416A1 (en) 2011-02-10
IL207212A (en) 2015-01-29
BRPI0906444A2 (pt) 2015-07-14
BRPI0906444A8 (pt) 2020-02-27
KR101596527B1 (ko) 2016-02-22
KR20100103636A (ko) 2010-09-27
JP2011510087A (ja) 2011-03-31
IL207212A0 (en) 2010-12-30
EP2235002A1 (en) 2010-10-06
EP2235002B1 (en) 2012-11-21
HK1143157A1 (en) 2010-12-24
WO2009094417A1 (en) 2009-07-30
PT2235002E (pt) 2013-01-30
PL2235002T3 (pl) 2013-04-30
US8258118B2 (en) 2012-09-04

Similar Documents

Publication Publication Date Title
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
CY1121858T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
CY1113323T1 (el) Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου
CY1111721T1 (el) Ακυλαμινοπυραζολια ως αναστολεις fgfr
CY1117776T1 (el) Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
CY1110990T1 (el) Παραγωγα αδενοσινης ως αγωνιστες υποδοχεων α2α
CY1119381T1 (el) Παραγωγα 2-μεθυλομορφολινο πυριδο-, πυραζο- και πυριμιδο-πυριμιδινης ως αναστολεις mtor
LTPA2016016I1 (lt) Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UY30500A1 (es) Compuestos de azabencimidazolilo
CY1118135T1 (el) Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων